According to the Skin Cancer Foundation: “Actinic keratosis (AK), also known as a solar keratosis, is a scaly or
crusty growth (lesion) caused by damage from the sun’s ultraviolet (UV) rays. They typically appear on sun-
exposed areas such as the face, bald scalp, lips, and the back of the hands, and are often elevated, rough in
texture, and resemble warts. Most become red, but some will be tan, pink, red, and/or flesh-toned. Untreated
AKs can advance to squamous cell carcinoma (SCC), the second most common form of skin cancer, and some
experts believe they are actually the earliest stage of SCC."
"It is generally accepted that more than 58 million Americans have actinic keratosis. People with a fair
complexion, blond or red hair, and blue, green or grey eyes have a high likelihood of developing one or more
of these common pre-cancers if they spend time in the sun and live long enough. The incidence is slightly
higher in men, because they tend to spend more time in the sun and use less sun protection than women do.”
Due to the fact that this condition is so common and can lead to skin cancer, pharmaceutical companies are
constantly searching for new and better treatments. Therefore Horizons often conducts research studies that
test investigational treatments for actinic keratosis. Although AK can be found on other parts of the body
these studies are typically looking for participants that have it on their face or balding scalp. You may be
eligible to participate in a clinical research study if that describes you.
Each AK study that we conduct has its own requirements for participation so please contact us to see if we
may have a study that is a good fit for you.
Participation in these studies is free of charge. You will receive all study related medical care and study
medication at no cost throughout the study. Qualified participants will also receive compensation for time and
travel. Insurance is not needed to participate.
For more information please call us at 303-399-4067, or complete the following questionnaire. We look
forward to hearing from you!